Climb Bio, Inc. Common Stock (CLYM) Stock
Fundamentals
Source: third-party data provider, as of October 13, 2026
Compare with CLYM
Recent news

Biotech Stocks Dive As Top 2% Names Take Hardest Hit
Biotech Stocks Dive As Top 2% Names Take Hardest Hit
CLYM

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
CLYM

Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
CLYM

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
CLYM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 32.71
- MACD 12/26/9
- -0.96
- EMA 9 of MACD
- -0.91
- MACD histogram
- -0.05
- SMA 50
- $13.89
- Price below SMA 50
- EMA 50
- $12.90
- Price below EMA 50
- SMA 200
- $9.97
- Price above SMA 200
- EMA 200
- $9.67
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Biotech Stocks Dive As Top 2% Names Take Hardest Hit
Biotech Stocks Dive As Top 2% Names Take Hardest Hit
CLYM

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
CLYM

Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded
CLYM

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
CLYM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Climb Bio, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | CEO, President & Director | 1976 |
| Dr. Susan Altschuller M.B.A., Ph.D. | CFO & Principal Accounting Officer | 1982 |
| Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer | 1979 |
| Mr. Adam Villa | Senior Vice President of Technical Operations | — |
| Ms. Chandra Adams J.D. | Senior VP, General Counsel & Secretary | — |
| Ms. Ashley Jones | Senior Vice President of People & Workforce Strategy | — |
| Dr. Edgar D. Charles M.D., M.Sc. | Chief Medical Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 13, 2026
Technical indicators
- RSI 14
- 32.71
- MACD 12/26/9
- -0.96
- EMA 9 of MACD
- -0.91
- MACD histogram
- -0.05
- SMA 50
- $13.89
- Price below SMA 50
- EMA 50
- $12.90
- Price below EMA 50
- SMA 200
- $9.97
- Price above SMA 200
- EMA 200
- $9.67
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 12, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $20.00
- Average
- $26.71
- High
- $32.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -24.9 | -15.4 | -44.8 | |||||||||
| 2025 | -8.2 | -27.1 | -9.6 | +11.7 | -6.3 | +5.1 | +17.6 | +53.8 | -9.9 | +4.1 | -5.5 | +123.5 |
| 2026 | +19.2 | +51.2 | -3.1 | +27.8 | +23.0 | +10.5 | -10.5 | +16.3 | -22.6 | -2.2 |



